Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, Ohio.
Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, Ohio.
Mod Pathol. 2023 Jan;36(1):100038. doi: 10.1016/j.modpat.2022.100038.
Similar to PAX8, SOX17 was recently identified as a master transcription factor of ovarian cancer based on RNA sequencing data. We explored SOX17 utility in diagnosing ovarian tumors and other gynecologic tumors. We systematically evaluated SOX17 expression on tissue microarrays of 398 ovarian tumors of various types, 93 endometrial carcinomas, 80 cervical carcinomas, and 1371 nongynecologic carcinomas, such as those of kidney, thyroid, breast, colon, bladder, liver, bile duct, adrenal gland, pancreas, brain, and lung and malignant melanoma. In addition, we evaluated SOX17 expression in whole tissue sections from 60 gynecologic carcinomas and 10 angiosarcomas. The results demonstrated that SOX17 was highly expressed in most ovarian and endometrial tumors with strong intensity. However, unlike PAX8, it was predominately negative in other tested tumor types, including kidney and thyroid tumors. In particular, SOX17 was highly expressed in the following pathologic subtypes of ovarian tumors: serous carcinoma, clear cell carcinoma, endometrioid carcinoma, and germ cell tumors. SOX17 was mostly negative in mucinous carcinoma and sex cord stromal tumors. In addition, SOX17 was expressed in vascular endothelial cells and was positive in all tested angiosarcomas. In summary, our results demonstrate that SOX17 is a sensitive and specific marker for ovarian nonmucinous carcinomas and endometrial carcinomas. For ovarian germ cell tumors and angiosarcomas, SOX17 demonstrates higher specificity than PAX8, with comparable sensitivity. Furthermore, SOX17 positivity in endothelial cells serves as an internal positive control, making it an excellent marker.
类似于 PAX8，SOX17 最近根据 RNA 测序数据被确定为卵巢癌的主转录因子。我们探索了 SOX17 在诊断卵巢肿瘤和其他妇科肿瘤中的应用。我们系统地评估了 SOX17 在 398 种不同类型的卵巢肿瘤、93 例子宫内膜癌、80 例宫颈癌和 1371 例非妇科肿瘤（如肾、甲状腺、乳腺、结肠、膀胱、肝、胆管、肾上腺、胰腺、脑和肺的恶性黑色素瘤）的组织微阵列上的表达。此外，我们还评估了 60 例妇科癌和 10 例血管肉瘤的全组织切片中的 SOX17 表达。结果表明，SOX17 在大多数卵巢和子宫内膜肿瘤中表达较高，强度较强。然而，与 PAX8 不同，它在其他测试的肿瘤类型中主要为阴性，包括肾和甲状腺肿瘤。特别是，SOX17 在以下卵巢肿瘤的病理亚型中表达较高：浆液性癌、透明细胞癌、子宫内膜样癌和生殖细胞肿瘤。SOX17 在黏液性癌和性索间质肿瘤中大多为阴性。此外，SOX17 在血管内皮细胞中表达，并且在所有测试的血管肉瘤中均为阳性。总之，我们的结果表明，SOX17 是卵巢非黏液性癌和子宫内膜癌的敏感和特异性标志物。对于卵巢生殖细胞肿瘤和血管肉瘤，SOX17 的特异性高于 PAX8，敏感性相当。此外，内皮细胞中的 SOX17 阳性可作为内部阳性对照，是一种极好的标志物。
